 | |
| Clinical data | |
|---|---|
| Trade names | Rezlidhia |
| Other names | FT-2102 |
| License data | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| PDB ligand | |
| Chemical and physical data | |
| Formula | C18H15ClN4O2 |
| Molar mass | 354.79 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Olutasidenib, sold under the brand nameRezlidhia, is ananticancer medication used to treat relapsed or refractoryacute myeloid leukemia with a susceptible IDH1 mutation.[1][2] Olutasidenib is anisocitrate dehydrogenase-1 (IDH1) inhibitor.[1] It is takenby mouth.[1]
The most common adverse reactions include nausea, fatigue/malaise, arthralgia, constipation, leukocytosis, dyspnea, fever, rash, mucositis, diarrhea, and transaminitis.[3]
Olutasidenib was approved for medical use in the United States in December 2022,[1][2][3][4][5][6] based on the phase 1 results of a phase 1/2 trial.[7]
Olutasidenib is indicated for the treatment of adults with relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.[1][2][3]
Olutasidenib is the international nonproprietary name.[8]
This article incorporates text from this source, which is in thepublic domain.